While the focus of anti-tumor immunity research has long been on MHC I and CD8 T cells, it has been shown in mouse models that the majority of immunogenic mutations are presented via MHC II and recognized by CD4 T cells [103]. This evidence concerns the gene CD8A and neoplasm.